![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Cellectis Gets FDA Approval for Third CAR-T Cell Trial
Cellectis Gets FDA Approval for Third CAR-T Cell Trial
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
June 7, 2018
The FDA approved an investigational new drug application from Cellectis for a Phase 1 clinical trial of UCART22, its third gene-edited CAR-T cell candidate.
The therapy uses engineered cells from healthy donors rather than a patient’s own cells. The approval comes the month after the French company submitted the IND, which aims to treat adult patients with B-cell acute lymphoblastic leukemia.
Cellectis plans to initiate a Phase I clinical study later this year at the University of Texas MD Anderson Cancer Center.
Upcoming Events
-
21Oct